Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Biora Therapeutics, Inc. - Common Stock (NQ: BIOR )

0.5936 +0.0966 (+19.44%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 24, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 853,125
Open 0.5430
Bid (Size) 0.5700 (99)
Ask (Size) 0.6000 (2)
Prev. Close 0.4970
Today's Range 0.5430 - 0.6100
52wk Range 0.4750 - 6.700
Shares Outstanding 4,063,081
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Why NetEase Shares Are Trading Lower? Here Are Other Stocks Moving In Friday's Mid-Day Session
Via Benzinga
Why Ross Stores Shares Are Trading Higher By Over 8%; Here Are 20 Stocks Moving Premarket
Via Benzinga

Performance

YTD
-55.37%
-55.37%
1 Month
-4.24%
-4.24%
3 Month
-30.07%
-30.07%
6 Month
-56.03%
-56.03%
1 Year
-86.69%
-86.69%

More News

Read More
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Biora Therapeutics: Q4 Earnings Insights
Via Benzinga
Earnings Outlook For Biora Therapeutics
Via Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
Biora Therapeutics Presents Clinical Data on Device Function of the NaviCap™ Platform at Digestive Disease Week 2024
From Biora Therapeutics, Inc.
Via GlobeNewswire
BIOR Stock Earnings: Biora Therapeutics Beats EPS for Q1 2024
Via InvestorPlace
Biora Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results
From Biora Therapeutics, Inc.
Via GlobeNewswire
Biora Therapeutics to Report First Quarter 2024 Financial Results and Provide Corporate Update
From Biora Therapeutics, Inc.
Via GlobeNewswire
Biora Therapeutics to Present Clinical Data on Device Function of the NaviCap™ Oral Delivery Platform at Digestive Disease Week 2024
From Biora Therapeutics, Inc.
Via GlobeNewswire
Biora Therapeutics Announces Completion of Multiple-Ascending Dose (MAD) Cohorts for Clinical Trial of BT-600
From Biora Therapeutics, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
Biora Therapeutics Announces New Patent Covering its BioJet™ Liquid Jet Delivery Technology
From Biora Therapeutics, Inc.
Via GlobeNewswire
Biora Therapeutics Achieves Positive Interim Results for Clinical Trial of BT-600, Advancing NaviCap™ Platform Development
From Biora Therapeutics, Inc.
Via GlobeNewswire
Biora Therapeutics Announces Closing of $6 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
From Biora Therapeutics, Inc.
Via GlobeNewswire
Why Nuvve Holding Shares Are Trading Lower By Around 30%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Biora Therapeutics Announces $6 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
From Biora Therapeutics, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
BIOR Stock Earnings: Biora Therapeutics Misses EPS for Q4 2023
Via InvestorPlace
Biora Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results
From Biora Therapeutics, Inc.
Via GlobeNewswire
Earnings Scheduled For March 26, 2024
Via Benzinga
Biora Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update
From Biora Therapeutics, Inc.
Via GlobeNewswire
Biora Therapeutics Further Reduces Net Debt and Monetizes Legacy Asset
From Biora Therapeutics, Inc.
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.